GSK plcGSK

GSK's oncology research focuses on Jemperli, a drug studied across various cohorts and indications. Safety findings for Jemperli include a 0.2% incidence of severe infusion-related reactions (Grade 3) and a 0.2% incidence of Grade 4 pneumonitis. Grade 3 pneumonitis incidence was 0.8%, while Grade 2 pneumonitis incidence was 1.3%. Other notable adverse events include a 0.7% incidence of Grade 3 adrenal insufficiency and a 0.5% incidence of Grade 2 adrenal insufficiency. Grade 3 colitis incidence was 0.7%.

In specific cohorts, Grade 3-4 TEAEs were observed in 91% of patients in Part 1A Cohort 0 and 80% in Part 1A Cohort 1B. Grade >=3 SAEs were reported in 55% of patients in Part 1A Cohort 0 and 67% in Part 1B. Immune-mediated adverse events included 1 patient with Grade 3 immune-mediated encephalitis in SCOOP and 14% with Grade 5 imAE of immune mediated encephalitis in Part 1A Cohort 1A. Grade >=3 or serious imAEs occurred in 11% of patients. Thrombocytopenia events were also noted, with 6 patients experiencing Grade 3-4 thrombocytopenia in SCOOP and 9 patients with Grade ≥3 TEAE of thrombocytopenia or platelet count decreased in SCOOP.